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ABSTRACT
Objectives: Currently there is no tool available to ade-
quately appraise the quality of the pediatric health eco-
nomics literature. A comprehensive pediatric-speciﬁc
instrument would be valuable in informing allocation
decisions related to pediatric interventions and services.
The goal of this study was to develop the Pediatric
Quality Appraisal Questionnaire (PQAQ).
Methods: A draft instrument was constructed from pub-
lished checklists and questionnaires. New questions per-
taining to the pediatric population were incorporated. An
expert panel reviewed the draft instrument and the pro-
posed scoring scheme for face and content validity. A
revised version was pilot tested by three independent
appraisers. After addressing discrepancies in scores, a
ﬁnal version was created and subjected to interrater and
test–retest reliability assessment.
Results: The 57 items in the ﬁnal PQAQ were mapped
onto 14 domains: economic evaluation, comparators, tar-
get population, time horizon, perspective, costs and
resource use, outcomes, quality of life, analysis, discount-
ing, incremental analysis, sensitivity analysis, conﬂict of
interest, and conclusions. Among the 57 items, 46 have
response options that are scored from 0 to 1. Interrater
reliability was 0.75 (95% conﬁdence interval [CI] 0.66–
0.81) and test–retest reliability was 0.92 (95% CI 0.71–
0.98).
Conclusions: The PQAQ is a comprehensive instrument
demonstrating face and content validity and strong inter-
rater and test–retest reliability in the appraisal of pediatric
economic evaluations. This tool will be valuable to health
economists, methods researchers, and policy decision
makers involved in allocation decisions for pediatric
health care.
Keywords: economic evaluation, pediatrics, publication,
quality appraisal.
Introduction
As health-care delivery becomes increasingly con-
strained by economic considerations, decision mak-
ers demand high-quality economic evaluations of
interventions, services, and technology to facilitate
allocation decisions. In recent years, standard meth-
ods for the conduct of economic evaluations have
evolved, catalyzed by growth in the pharmaceutical
sector [1,2]. Nevertheless, the validity of applying
standard health economic methods to a pediatric
population has yet to be examined. Health eco-
nomic evaluations of pediatric interventions must
recognize that children rely on parents, teachers,
and others to provide access to health care and to
report on the use of health resources; that recom-
mended outcomes such as quality-adjusted life-
years or willingness to pay may be difﬁcult to assess
in children; and that different outcome measures
corresponding to successive stages of physical devel-
opment may be required [3–7].
As a ﬁrst step in a research program in pediatric
health economic methods, a comprehensive data-
base of all pediatric economic evaluations published
from 1980 to 1999 was created [8]. With this data-
base available, an important research objective was
to evaluate the quality of published pediatric eco-
nomic evaluations. Nevertheless, existing economic
appraisal instruments appeared inadequate for the
formal appraisal of the pediatric literature. These
instruments do not include items related to parent/
caregiver proxy reporting for outcomes and for
health resource use, do not capture time losses of
parents and caregivers, do not assess the need for an
adequate time horizon to capture future costs and
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consequences, do not consider pediatric quality of
life, and do not address the family as a unit of
analysis. Thus, there remained a need to develop a
pediatric-speciﬁc quality appraisal instrument. This
article describes the systematic development and
testing of a new instrument, the Pediatric Quality
Appraisal Questionnaire (PQAQ).
Methods
The PQAQ was developed through a formal process
of item selection and reduction, domain construc-
tion, assignment of response options, development
of a scoring scheme, external review, pretesting, and
reliability assessment.
Initial Questionnaire Construction
A comprehensive initial version of the PQAQ was
constructed based on published checklists and
questionnaires that evaluated the quality-of-health
economic evaluations [9–24]. These published
instruments appraised research published in
pharmacy, medical, or health economics journals
[12,14–18] or economic studies employing a
particular analytic technique, such as cost–beneﬁt
analysis (CBA), cost-effectiveness analysis (CEA),
or cost-utility analysis (CUA) [9,11,13,22,24]. In
addition to instruments found in peer-reviewed
journals, those available from public agencies and
textbooks were reviewed [19,20]. Because available
instruments lacked items that address the measure-
ment of pediatric and parental costs and conse-
quences, questions pertaining to the pediatric
population were newly formulated. Several existing
instruments ask the appraiser to rate the appro-
priateness of analytic steps, such as costing and
modeling. However, many issues in economic eval-
uation method remain controversial, and rating
the appropriateness of the evaluation components
could be subjective. In the development of the
PQAQ, a deliberately comprehensive approach was
taken. “Appropriate” costing could be deﬁned as
including all relevant cost items, including produc-
tivity and time costs when necessary, including costs
borne outside the health-care system, and citing the
sources for resource use volume and prices. The
preferred approach was to break down the deﬁni-
tion of “appropriate” by including a series of yes
or no questions regarding each step. Whereas this
increases the number of items in a questionnaire, it
reduces subjectivity. Related items were grouped
together in domains based on established instru-
ments and based on themes emphasized in pub-
lished guidelines for economic evaluation [9–12,14–
20,22–24].
External Review
A seven-member expert panel was assembled to
assess the face and content validity of the draft
PQAQ. This consisted of ensuring that all relevant
items were included and evaluating the proposed
scoring approach. The panel was chosen to repre-
sent expertise in health economic methods, quality
appraisal of health economic publications, and
pediatric research. Several members were non-
Canadian or had extensive experience in interna-
tional health economic appraisal. As part of the
external review, the experts were asked to: 1) com-
ment on the wording of the questions and recom-
mend the deletion or addition of items; 2) rate each
question as having high, medium, or low impor-
tance for inclusion in the PQAQ; and 3) comment
on the various options for scoring the PQAQ and/or
provide suggestions for alternative scoring schemes.
Based on the experts’ ratings of each item in the
PQAQ as having high, medium, or low importance
for inclusion, a distribution pattern of ratings for
each item was determined. The frequency for each
possible pattern of response distribution was calcu-
lated. “Strong” agreement among experts was spec-
iﬁed if ﬁve or more experts agreed on the particular
rating of high, medium, or low. If four experts
agreed on the rating, a “medium” level of agree-
ment was assigned. If agreement was found between
three experts or fewer, the level of agreement was
designated as “weak.”
The agreement between the experts’ rating of
highly important items and published economic
evaluation quality appraisal instruments was evalu-
ated by calculating the percent observed agreement
and a kappa coefﬁcient. A rating was classiﬁed as
high if ﬁve or more experts rated the item as having
high importance and if the item appeared in four or
more published instruments.
PQAQ Scoring
The PQAQ responses were all categorical. Most
of the items had response options that followed
the following format: yes (explicitly stated); yes
(inferred from text, tables, or ﬁgures); no;
unknown/not stated/cannot tell; or not applicable.
Distinguishing between explicitly and implicitly
stated responses was based on instruments from
the literature that used similar approaches
[14,15,17,18,22]. For these items, full weight could
be given to explicit required elements, and partial
weight to elements that were implied. Several
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options for overall scoring of the PQAQ were pre-
sented to the experts. These included calculating
a summary score based on equally weighted items,
calculating a summary score based on weighting
items according to importance, or calculating a
summary score where only items of high impor-
tance were included. Other options included cal-
culating domain scores based on equally weighted
items within each domain or calculating domain
scores based on items weighted by importance
within each domain. The PQAQ also included sev-
eral questions that were descriptive and would not
be scored. These items added information about
methodology that could further characterize the lit-
erature and explain the observed results.
Pilot Testing the PQAQ
Based on the external reviewers’ comments, modi-
ﬁcations were made to construct the pilot PQAQ.
For the pilot test, 10 articles representative of the
various analytic techniques including CEA, CBA,
CUA, and cost-minimization analysis (CMA),
and 5-year periods (1980–1984, 1985–1989, 1990–
1994, and 1995–1999) were appraised. The pilot
version of the PQAQ had 64 items, including scora-
ble and descriptive items. Pilot testing a question-
naire with maximum comprehensiveness enabled us
to subsequently delete items that were found to be
redundant, invalid, or difﬁcult to interpret. Three
independent appraisers with experience in health
economic evaluation reviewed each article. The
scores for each question were compared among the
three appraisers.
Reliability Assessment
For reliability testing, a 20% random sample of
articles, stratiﬁed by 5-year period, was selected
from a comprehensive database of pediatric eco-
nomic evaluations published from January 1, 1980,
to December 31, 1999 [8]. A total of 150 articles,
in which the journal name, authors, and year were
concealed, were distributed to two independent
appraisers at two institutions. A database was
developed using ACCESS 97 (1997, Microsoft
Corp., Redmond, WA) to input the data from the
completed questionnaires. The ﬁnal PQAQ under-
went both interrater and test–retest reliability
assessment.
Interrater reliability is an indication of the con-
sistency in responses between multiple users of the
PQAQ. For the interrater reliability assessment,
one reviewer completed appraisals of 150 papers,
whereas the second completed appraisals for 149
papers. The results are presented for the 149 papers
appraised by both reviewers. An intraclass correla-
tion coefﬁcient was calculated for each domain to
assess interrater reliability. Each intraclass correla-
tion coefﬁcient was calculated from a repeated-
measures analysis of variance (ANOVA) using a
two-way mixed model and a consistency type of
index. Ninety-ﬁve percent conﬁdence intervals (CI)
were computed for the intraclass correlation coefﬁ-
cient. These analyses permitted the detection of sys-
tematic differences between the raters. In addition
to domain scores, a total PQAQ score was used as
a convenient summary measure for interrater relia-
bility. To calculate the total questionnaire score, the
scores from each of the applicable scorable items in
the ﬁnal PQAQ were summed together and then
divided by the total number of items.
The purpose of test–retest reliability assessment
is to measure the consistency of responses within a
rater. In this case, one of the above appraisers
reevaluated 10 papers from the initial batch of 150
papers 2 months later. An intraclass correlation
coefﬁcient and 95% CI were calculated using the
repeated-measures ANOVA. The test–retest reliabil-
ity was evaluated for the total score and the domain
scores.
Results
In the ﬁnal version of the PQAQ, items were
grouped into 14 domains: economic evaluation,
comparators, target population, time horizon, per-
spective, costs and resource use, outcomes, quality
of life, analysis, discounting, incremental analysis,
sensitivity analysis, conﬂict of interest, and conclu-
sions. The number of items in a domain varied from
2 to 10 with an average of 4. The ﬁnal version
included 46 scorable items and 10 items that added
descriptive information. A global quality assess-
ment was included as the ﬁnal PQAQ item. This
yielded a total of 57 items. The PQAQ is presented
in Appendix 1.
External Review
The expert panel rated the inclusion of each item in
the draft questionnaire as having high, medium, or
low importance. Ratings were not received for some
of the items; there were 48 items with ratings by
all seven experts. Table 1 illustrates that there was
strong concordance among the experts regarding
the rating for 42% of the PQAQ items, medium
concordance for 31% of the items, and weak con-
cordance on rating item importance for 27% of the
items.
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Table 2 presents the level of agreement between
the experts and the literature regarding the rating of
items having high importance. The percentage of
observed agreement was 81% and the chance-cor-
rected agreement was moderate, with kappa equal
to 0.57 (95% CI 0.32–0.82). There was variation
among the experts regarding which items were
important to include. There were 28 items that four
or fewer experts rated as important for inclusion
and that also appeared in fewer than four published
quality appraisal instruments. Because these items
represent contentious issues rather than items for
which there was consensus for exclusion, almost all
of these items were retained. A comprehensive
approach was taken whereby items considered
important by the experts or by the literature were
retained. Some of the items rated as important by
the experts but not by the literature pertained to the
pediatric population and were therefore absent
from published questionnaires. There were no items
that ﬁve or more experts rated as having low
importance.
PQAQ Scoring
There was a consensus among the experts that a lin-
ear additive total score based on equally weighted
items would not be useful. The items included in
each of the study domains represent important the-
matic components of an economic evaluation. It
would therefore be inappropriate to allow a high
score for a particular domain to compensate for a
low score on another domain. It was also agreed
that weighting the domains equally to calculate a
total score would be difﬁcult to justify. It was
resolved that whereas a single summary measure
would not be of value, domain subscores would be
informative.
The PQAQ was designed to maximize the
number of scorable items. A comprehensive ap-
proach that asks appraisers to determine the pre-
sence or absence of required elements rather than
rate the appropriateness of the methods used was
preferred. Among the 57 items in the ﬁnal PQAQ,
46 have response options that are scorable and use
the same response options. An example of how an
item is scored is presented in Table 3. Full item
weight (1.0) is assigned if the required element is
explicit whereas partial weight (0.5) is assigned if
the required element is implied. A score for each
domain is calculated by taking the mean score of all
the scorable items in that domain. Each domain
score has a range from 0 to 1. Not all items are
applicable for all publications. For example, if a
study included only a single perspective, then ques-
tion 15 was not applicable and was removed from
the calculation of the score for the perspective
domain. Except for summarizing the reliability
assessment, the PQAQ does not have a total score.
Pilot Testing
For the pilot test of the PQAQ, three appraisers
independently reviewed 10 published pediatric eco-
nomic evaluations. Table 4 illustrates the number of
Table 1 Agreement among experts regarding questionnaire item rating
Distribution patterns Number of items with distribution Concordance
All seven experts agreed on item rating 2 Strong
Six of seven experts agreed on item rating 10
At least ﬁve experts agreed on item rating 8
(n = 20 items; frequency 42%)
Four experts agreed on item rating 15
(n =15 items; frequency 31%)
Medium
No more than three experts agreed on
item rating
13
(n = 13 items; frequency 27%)
Weak
Table 2 Agreement between experts and literature




Yes 11 4 15
No 5 28 34
Total 16 32 48
*Observed agreement 0.81; κ = 0.57; 95% CI 0.32–0.82.
Table 3 Example of response option scoring
15. When there is more than one perspective, are the results of each 
perspective presented separately?
Yes (explicitly stated) 1.0
Yes (inferred from text, tables, or ﬁgures) 0.5
No 0.0
Not applicable Item not included
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questions for each article in which all three, two out
of three, or no appraisers agreed on the response.
The appraisers had a high tendency to agree. Three
of three appraisers were in agreement for scoring of
48% of items and two of three were in agreement
for an additional 44% of items. Only 8% of items
displayed no agreement among appraisers. Follow-
ing the pilot test, discussions were held to address
discrepancies and review the evaluation process
of each appraiser. Questions were subsequently
reworded to improve clarity and detailed compan-
ion rules for completing the PQAQ were created.
These rules were developed to ensure consistency
across multiple users.
Reliability Assessment
Two independent reviewers blinded to the study
authors and journal conducted quality appraisals of
a random sample of pediatric health economic
publications spanning a 20-year period from 1980
through 1999. The results are presented for 149
papers appraised by both reviewers.
As seen in Table 5, high interrater reliability, as
assessed by the intraclass correlation coefﬁcient,
was observed for discounting, sensitivity analysis,
conﬂict of interest, and perspective. Low interrater
reliability was observed for target population, time
horizon, outcomes, and conclusions. The remaining
domains demonstrated intermediate interrater reli-
ability. The interrater reliability was 0.75 for the
overall PQAQ.
The results of the test–retest reliability assess-
ment are displayed in Table 6. High test–retest reli-
ability was observed for almost all domains. Low
test–retest reliability was observed for target popu-
lation and conclusions. The test–retest reliability
was 0.92 for the overall PQAQ.
Discussion
Similar to the adult health economic literature
[25,26], the number of pediatric studies published
every year is rising [8]. This growth reﬂects the
importance of assessments of the economic beneﬁt
of interventions, programs, and services for children
in a health-care climate characterized by economic
constraints and difﬁcult allocation decisions. To be
of greatest value in informing allocation decisions,
Table 4 Pilot test results
Paper identiﬁcation
number Year
No. of questions (%)
with three of three agreed
No. of questions (%)
with two of three agreed
No. of questions (%) 
with zero of three agreed
370 1982 30 (47) 28 (44) 6 (9)
351 1986 32 (50) 28 (44) 4 (6)
440 1986 28 (44) 32 (50) 4 (6)
529 1987 29 (45) 27 (42) 8 (13)
7 1994 28 (44) 31 (48) 5 (8)
243 1994 30 (47) 28 (44) 6 (9)
519 1995 36 (56) 22 (34) 6 (9)
314 1996 35 (55) 25 (39) 4 (6)
499 1998 30 (47) 31 (48) 3 (5)
713 1999 32 (50) 28 (44) 4 (6)
Average 31 (48) 28 (44) 5 (8)




Economic evaluation 0.53 0.41–0.64
Comparators 0.53 0.41–0.64
Target population 0.15 −0.01–0.31
Time horizon 0.25 0.09–0.39
Perspective 0.81 0.74–0.86




Incremental analysis 0.47 0.34–0.59
Sensitivity analysis 0.83 0.77–0.87
Conﬂict of interest 0.82 0.76–0.87
Conclusions 0.37 0.22–0.50
Total questionaire score 0.75 0.66–0.81




Economic evaluation 0.86 0.55–0.96
Comparators 0.83 0.46–0.96
Target population −0.29 −0.76–0.37
Time horizon 0.71 0.20–0.92
Perspective 0.81 0.40–0.95




Incremental analysis 0.76 0.29–0.93
Sensitivity analysis 0.89 0.62–0.97
Conﬂict of interest 0.79 0.35–0.94
Conclusions 0.58 −0.03–0.88
Total questionnaire score 0.92 0.71–0.98
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an economic evaluation must be of high quality. A
variety of quality appraisal instruments are cur-
rently available for the assessment of the adult
literature [9–24]. The majority of these appraise key
aspects of economic evaluation, including com-
parators, perspective, costs, outcomes, discounting,
incremental analysis, sensitivity analysis, and con-
clusions. There is less consistency regarding speciﬁ-
cation of the analytic technique, the time horizon,
the target population, quality-of-life measure-
ment, transparency of the analysis, and study limi-
tations. Many instruments provide no scoring
[9,11,16,21,24]. Others utilize Likert-type scales
for scoring each item, with options such as incor-
rect, not reported, doubtful, acceptable, and correct
[10,14,15,17,18,22]. Instruments that calculated
total scores typically took an average value
[10,15,18,22]. Assessments of reliability or validity
were usually lacking. All of these instruments fail to
capture the unique aspects of pediatric health eco-
nomic evaluation. In particular, adult instruments
lack items related to time costs of parents and
caregivers, future productivity costs of children,
health-related resource utilization outside the
health-care system, children’s quality of life, paren-
tal proxy assessment, and a family or parent–child
unit of analysis. The PQAQ is the ﬁrst quality
appraisal instrument specially designed for applica-
tion in the pediatric population. It is a comprehen-
sive, 57-item questionnaire with strong test–retest
and interrater reliability.
In addition to appraising the quality of published
articles, the PQAQ could be used to determine the
adequacy and transparency of pediatric health eco-
nomic grant proposals and study protocols. Such an
instrument would be of value not only to academic
researchers, but also allocation decision makers
associated with government health programs, man-
aged care organizations, and health-care institu-
tions. Because the PQAQ is not associated with a
particular country or type of health-care system, it
has relevance for international appraisals and eval-
uations of the pediatric literature.
A number of hurdles were encountered during
the development of the PQAQ. Given the interna-
tional movement toward standardizing health eco-
nomic methods and guideline development that has
occurred in recent years [1,2,19,27–29], one would
have expected stronger agreement among experts
as to what items should be included or excluded
in the PQAQ. A high level of agreement among
the experts was observed for only 42% of the items,
suggesting that uncertainty persists regarding the
required elements in an economic evaluation.
Determining the optimal scoring technique for
the PQAQ presented a challenge. There was con-
sensus among the members of our expert panel that
it would be inappropriate to assume equal weight
among all items in the questionnaire to calculate a
simple total score. It was also problematic to assign
weights to individual items to determine a single
summary score. A single summary score was unten-
able and it would have proven too complex to
present individual item scores. A reasonable com-
promise was to present scores for each of the 14
domains, where each pertained to a critical aspect
of economic evaluation.
Similarly, in the assessment of reliability, it would
be ideal to calculate intraclass correlations for each
item because of the possibility that item correlations
within a domain may oppose each other, thus bias-
ing the domain coefﬁcient. The current approach
was chosen because calculating item-speciﬁc intra-
class correlation coefﬁcients would present unnec-
essary complexity and would be difﬁcult to
interpret.
One domain that posed a problem was target
population, with very low interrater and test–retest
reliability. It may be that appraisers are not accus-
tomed to responding to questions regarding the tar-
get population when reviewing an article. Whereas
removing the two items comprising this domain
may improve the overall performance of the PQAQ,
these questions are important for ultimately de-
ciding if the article has relevance for an allocation
decision in a particular population. Because inter-
ventions for children are often approved on the
basis of adult studies, it was believed that it was
important to retain this domain and to provide clear
instructions to appraisers regarding interpretation
of this item.
Finally, for the purpose of this project, only stud-
ies that reported results for a distinct pediatric pop-
ulation could be appraised. Thus if a study assessed
both children and adults, the instrument could only
be used if the methods and results for children were
reported separately.
Conclusion
A sign of the growth and maturation of a scientiﬁc
discipline is the budding of new branches and sub-
disciplines. As the ﬁeld of health economics evolves
and as economic evaluation activity increases, the
limitations of existing methods begin to be revealed.
This necessitates novel research into addressing
these limitations and results in expansion of the
ﬁeld. The research described herein demonstrates
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that the infancy period of health economic appraisal
has ended, with attention now being paid to the
unique problems associated with applying standard
methods to special populations. The PQAQ focuses
attention on the conduct of health economic studies
in children. The PQAQ may provide an accurate
estimate of the quality of pediatric health economic
evaluations to better inform allocation decision
making. This project may also spur methodologic
investigations into the unique challenges associated
with conducting health economic evaluations in the
pediatric population.
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Appendix 1
The Pediatric Quality Appraisal Questionnaire (Version 1.0, August 2001)
Economic Evaluation
1. Is the research question posed in terms of costs and consequences?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
2. Is a speciﬁc type of economic analysis technique performed?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
3. What type of analytic technique is performed, according to the authors?
 1. CMA;  2. CEA;  3. CBA;  4. CUA;  5. Cost-consequence analysis;  6. Unknown/
cannot tell;  7. Other (specify: __________)
Comparators
4. Is there a rationale for choosing the intervention(s) being investigated?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
5. Is there a rationale for choosing the alternative program(s) or intervention(s) used for comparison?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures).  3. No
6. Does the report describe the alternatives in adequate detail?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
7. Is a description of the event pathway provided?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
8. Is a formal decision analysis performed?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated
Target Population
9. Is the target population for the intervention identiﬁed?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
10. Are the subjects representative of the population to which the intervention is targeted?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated/cannot tell;  5. Not applicable
Ungar and Santos592
Time Horizon
11. Is there a time horizon for both costs and outcomes?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
12. Do the authors justify the time horizon selected?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
Perspective
13. Is a perspective for the analysis given?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
14. Is a societal perspective taken, either alone or in addition to other perspectives?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated
15. When there is more than one perspective, are the results of each perspective presented separately?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
Costs and Resource Use
16. Are all relevant costs for each alternative included?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
17. Are opportunity costs of lost time (productivity costs) for parents and informal caregivers measured
when required?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated;  5. Not applicable
18. Do cost item identiﬁcation and valuation extend beyond the health-care system to include school and
community resources when necessary?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated;  5. Not applicable
19. Are future salary and productivity changes of the child taken into consideration when appropriate?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated;  5. Not applicable
20. Are all of the sources for estimating the volume of resource use described?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
21. Are all the sources for estimating all of the unit costs described?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
Outcomes
22. Is a primary health outcome given?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
23. Do the authors justify the health outcome(s) selected?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
24. Is effectiveness, rather than efﬁcacy, assessed?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated/cannot tell
25. What approach is used to assess the effectiveness/efﬁcacy?
 1. Prospective data collection;  2. Retrospective data collection;  3. Literature sources;
 4. Expert opinion;  5. Other (specify: __________)
26. Are the details of the design of the effectiveness/efﬁcacy study(s) provided?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
27. Are the results of the efﬁcacy/effectiveness of alternatives reported?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
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28. Are school/day-care absences taken into consideration?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
29. If intermediate outcome variables are used, are they linked by evidence or reference to the end beneﬁt?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
Quality of Life
30. If quality of life is measured, what type of instrument is used?
 1. Disease-speciﬁc;  2. Generic, standard instrument;  3. Generic, direct preference;
 4. Generic, indirect preference;  5. Other  (specify: __________);  6. Not applicable
31. Whose quality of life is assessed?
 1. Child;  2. Parent;  3. Caregiver (if OTHER than parent);  4. Other (specify: __________);
 5. Not applicable
32. Who performed the quality-of-life assessment?
 1. Self-assessment (child, parent, or caregiver);  2. Parent on behalf of child;  3. Caregiver on
behalf or child;  4. Health-care provider on behalf of child;  5. Other (specify: __________);
 6. Not applicable
Analysis
33. Are costs AND outcomes measured in units appropriate for the indicated analytic technique?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated
34. For prospective studies that use interviews, questionnaires, or surveys, how are data obtained in studies
involving young children?
 1. Directly;  2. Parent proxy;  3. Other proxy (specify: __________);  4. Joint measure
(specify: __________);  5. Not applicable
35. How are direct costs valued?
 1. Opportunity cost;  2. Fixed, overhead, capital, or administrative costs;  3. Charges or fees;
 4. Deﬂated charges (using cost to charge ratios);  5. Market or wholesale prices or replacement
costs;  6. Average cost (per patient-day, etc.);  7. Assumption, opinion, or expert panel;
 8. Unknown/not stated;  9. Other (specify: __________)
36. How are productivity costs valued?
 1. Market value approach;  2. Opportunity cost approach;  3. Average statistical wage
from population database;  4. Friction cost method;  5. Other method (specify: __________);
 6. Not applicable
37. Are costs valued appropriately?
 1. Yes (explicitly stated);  2 Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated/cannot tell
38. Is the valuation of outcomes appropriate for the type of analysis?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated/cannot tell
39. What is the unit of analysis used for expressing the ﬁnal results?
 1. Per child or patient or case;  2. Per parent;  3. Per family;  4. Per joint parent–child;
 5. Per patient sample or study sample;  6. Per population (e.g., per 10,000 or whole population)
40. Are quantities of resources used reported separately from their unit costs?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
41. Are the costs aggregated correctly?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated/cannot tell;  5. Not applicable
42. Are details of statistical tests and conﬁdence intervals given for stochastic data?




43. When required, are costs and consequences that occur over more than 1 year discounted to their present
values?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Unknown/
not stated;  5. Not applicable
44. If costs or beneﬁts are not discounted when the time horizon exceeds 1 year, is an explanation provided?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
Incremental Analysis
45. Are incremental estimates of costs and outcomes presented?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
46. Are the incremental estimates summarized as incremental ratios?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
47. Are conﬁdence intervals/limits calculated for incremental ratios or incremental estimates of costs and
outcomes?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
Sensitivity Analysis
48. Are all important assumptions given?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
49. Is a sensitivity analysis performed?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
50. Do the authors justify the alternative values or ranges for sensitivity analysis?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
51. What methods are used to assess uncertainty?
 1. One-way sensitivity analysis;  2. Two-way sensitivity analysis;  3. Multiway sensitivity anal-
ysis;  4. Bootstrapping or Monte Carlo simulations;  5. Other (specify: __________);  6. None
performed
Conﬂict of Interest
52. Does the article present the relationship with the sponsor of the study?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
53. Does the article indicate that the authors had independent control over the methods and right to
publish?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No;  4. Not
applicable
Conclusions
54. Is the answer to the study question provided?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
55. Are the most important limitations of the study discussed?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
56. Do the authors generalize the conclusions to other settings or patient/client groups?
 1. Yes (explicitly stated);  2. Yes (inferred from text, tables, or ﬁgures);  3. No
57. Global impression of the quality of the article.
 1. Excellent;  2. Very good;  3. Good;  4. Fair;  5. Poor;  6. Worthless
